Modeling the Potential Public Health Impact of Updated COVID-19 Vaccination Strategies in Singapore: Epidemiological Data Update [0.03%]
更新的新冠疫苗接种策略对新加坡公共卫产生潜omicsTKI的影响：流行病学数据更新
Karan Thakkar,Moe H Kyaw,Iustina Chirila et al.
Karan Thakkar et al.
Introduction: This study estimated the potential public health impact of alternative COVID-19 vaccination strategies in Singapore. Methods: ...
Drug-Induced Pulmonary Toxicity in the Era of Immunotherapy and Biologics: A Narrative Review of Mechanism, Diagnosis, and Management [0.03%]
免疫治疗和生物制剂时代药物诱发肺毒性的机制、诊断及处理措施：叙述性回顾
Josmar J Ríos Poveda,Manuela Herrera Tamayo,Juan J Zapata Huizi et al.
Josmar J Ríos Poveda et al.
Drug-induced interstitial lung disease (DI-ILD) has emerged as a clinically significant complication associated with a broadening spectrum of therapeutic agents. DI-ILD can result in significant morbidity and mortality if not promptly diagn...
Kai Xian Thng,Micheál Mac Aogáin,Sanjay H Chotirmall
Kai Xian Thng
Emerging evidence demonstrates the evolving role of fungi in the pathophysiology and disease progression observed in bronchiectasis. Fungal-associated traits are linked to disease severity, exacerbation frequency and airway inflammation. St...
Real-World Treatment Patterns and Burden of Chronic Thromboembolic Pulmonary Hypertension Patients across Consultation Settings in the USA [0.03%]
美国多学科门诊环境中慢性血栓性肺动脉高压患者的治疗模式和疾病负担
Belinda Rivera-Lebron,Alison Witkin,Carly J Paoli et al.
Belinda Rivera-Lebron et al.
Introduction: Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, progressive pulmonary hypertension characterized by chronic fibrotic thrombi. Treatment includes surgical, endovascular, and pharmaceutical op...
Home-Based FeNO Monitoring with the Vivatmo me Device Reveals Type 2 Inflammatory Patterns of Patients with Asthma at Different Treatment Steps: The FeNO@Home Study [0.03%]
基于Vivatmo me设备的家庭FeNO监测显示，不同治疗阶段哮喘患者的2型炎症模式：FeNO@家研究
Kai M Beeh,Tim Harrison,Enrico Heffler et al.
Kai M Beeh et al.
Introduction: Fractional exhaled nitric oxide (FeNO) is an important type 2 (T2) asthma biomarker. Home-based FeNO monitoring can provide longitudinal data better reflecting the variable nature of T2 inflammation versus s...
Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Italy: A Retrospective Study from a Cystic Fibrosis Center [0.03%]
意大利一项关于Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA)的回顾性研究：一家囊性纤维化中心的现实世界影响
Marco Cipolli,Teja Thorat,Pia C Pafundi et al.
Marco Cipolli et al.
Introduction: In Italy, elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in combination with ivacaftor was reimbursed starting July 2021 for use in people with cystic fibrosis (CF) aged ≥ 12 years homozygous for F508del mu...
Misconceptions of Traits to Predict Response to Inhaled Corticosteroid and Bronchodilator Therapies in Asthma: A Narrative Review [0.03%]
哮喘误用性状预测气道炎症表型和吸入糖皮质激素及支气管舒张剂反应的误区：综述性文章
Guy Brusselle,Jodie Crawford,Peter G Gibson et al.
Guy Brusselle et al.
The "treatable traits" approach to asthma management has helped revolutionize severe asthma treatment with biologic therapy and includes using biomarkers to identify patients most likely to benefit from a specific treatment. The ability to ...
Hyperbaric Oxygen Therapy and Its Physio-Mechanical Effects on Sleep Breathing Disorder: A Systematic Review [0.03%]
高压氧治疗及其对睡眠呼吸障碍的生理力学影响：系统性综述
Sy Duong-Quy,Tran V Hoc,Thai Nguyen-Duy et al.
Sy Duong-Quy et al.
Introduction: Hyperbaric oxygen therapy (HBOT), traditionally used for decompression sickness and chronic wounds, has recently attracted interest for its potential role in sleep breathing disorders (SBD). Because sleep is...
Bronchiectasis Treatment Goals, Unmet Needs, and Emerging Therapies: A Podcast [0.03%]
支气管扩张症的治疗目标、未满足的需求和新兴疗法：一期节目访谈
Patrick A Flume,Diego J Maselli
Patrick A Flume
Bronchiectasis is a chronic and progressive inflammatory lung disease characterized by dilated airways, impaired mucociliary clearance, recurrent infections, and inflammation. In this podcast, we discuss the heterogeneous causes and complex...
Correction: Dupilumab Versus Mepolizumab for COPD: Evaluating Efficacy Outcomes Using Placebo-Adjusted Indirect Treatment Comparison [0.03%]
杜普利尤单抗与美泊利单抗治疗慢性阻塞性肺疾病疗效的间接比拟分析：对随机临床试验数据进行安慰剂调整后的结果报道纠正声明
Surya P Bhatt,Nick Freemantle,Mena Soliman et al.
Surya P Bhatt et al.
Published Erratum
Pulmonary therapy. 2025 Nov 18. DOI:10.1007/s41030-025-00332-z 2025